Dolce Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 13-01-2025
- Paid Up Capital ₹ 3.50 Cr
as on 13-01-2025
- Company Age 30 Year, 2 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 13.70 Cr
as on 13-01-2025
- Revenue 145285.00%
(FY 2019)
- Profit -295.53%
(FY 2019)
- Ebitda 108.70%
(FY 2019)
- Net Worth -73.39%
(FY 2019)
- Total Assets 197.28%
(FY 2019)
About Dolce Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company currently has active open charges totaling ₹13.70 Cr.
Milind Gadkari, Rakhi Nair, and Gopakumar Nair serve as directors at the Company.
- CIN/LLPIN
U24200MH1994PTC083218
- Company No.
083218
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 1994
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dolce Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Milind Gadkari  | Director | 05-Mar-2016 | Current |
| Rakhi Nair | Director | 23-Mar-2010 | Current |
| Gopakumar Nair | Director | 23-Mar-2010 | Current |
Financial Performance of Dolce Pharmaceuticals.
Dolce Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 145285% increase. The company also saw a substantial fall in profitability, with a 295.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 73.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dolce Pharmaceuticals?
In 2019, Dolce Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹13.70 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 13.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Feb 2018 | Others | ₹13.70 Cr | Open |
How Many Employees Work at Dolce Pharmaceuticals?
Unlock and access historical data on people associated with Dolce Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dolce Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dolce Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
